Three cancer drugs have been added to the interaction checker

Acalabrutinib, blinatumomab and inotuzumab ozogamicin are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications.

• Acalabrutinib (Calquence®) is a Bruton’s tyrosine kinase inhibitor and is indicated for the treatment of mantle cell leukemia.
• Blinatumomab (Blincyto®) is a bispecific CD19-directed CD3 T-cell engager and is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia. 
• Inotuzumab ozogamicin (Besponsa®) is a CD22-directed antibody-drug conjugate and is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia.